

# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

11<sup>th</sup> August 2022



The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jheejheebhoy Towers,  
Dalal Street,  
Mumbai – 400 001.  
**Scrip Code – 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra – Kurla Complex  
Bandra (E)  
Mumbai – 400 051.  
**Scrip Code–**  
**APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sir,

## **Sub: Decisions at the Board Meeting held on 11<sup>th</sup> August 2022**

Further to our letters dated 27<sup>th</sup> June and 26<sup>th</sup> July 2022, the Board of Directors at the meeting held on 11<sup>th</sup> August 2022 have approved the unaudited financial results of the Company for the quarter ended 30<sup>th</sup> June 2022.

As required by the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (LODR) we enclose/furnish the following particulars.

1. Unaudited financial results (both standalone and consolidated) of the Company for the quarter ended 30<sup>th</sup> June 2022, which have been subjected to Limited Review by the Statutory Auditors of the Company – enclosed as Annexure I.
2. Copy of the Limited Review Report of the Statutory Auditors for the corresponding period.
3. The financial results will also be published in the newspapers, in the format prescribed under Regulation 47 of the Listing Regulations.
4. The said documents are being posted on the website of the Company i.e., [www.apollohospitals.com](http://www.apollohospitals.com).

The meeting of the Board of Directors commenced at 4.00 p.m. and concluded at 6.30 p.m.

Please take note of the above in your records.

Thanking you,

Yours faithfully,  
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN  
Sr. VICE PRESIDENT – FINANCE  
AND COMPANY SECRETARY

IS/ISO 9001:2000

**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers", III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website: [www.apollohospitals.com](http://www.apollohospitals.com)

Apollo Hospitals Enterprise Limited  
Corporate Identity Number : L85110TN1979PLC008035  
Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu  
Tel No. 44-28290956 , Email : investor.relations@apollohospitals.com  
Website: www.apollohospitals.com

Statement of Unaudited Standalone Financial Results for the three months ended June 30, 2022

(Rs. in lakhs)

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b><u>Continuing Operations</u></b>				
<b>1 Income</b>				
(a) Revenue from Operations	1,52,969	1,42,073	1,48,271	6,09,833
(b) Other Income	1,052	1,866	840	4,699
<b>Total Income (a + b)</b>	<b>1,54,021</b>	<b>1,43,939</b>	<b>1,49,111</b>	<b>6,14,532</b>
<b>2 Expenses</b>				
(a) Cost of Materials Consumed	46,429	41,531	37,770	1,92,933
(b) Purchases of Stock-in-Trade	-	-	17,962	-
(c) Changes in inventories of stock-in-trade	-	-	(8,272)	-
(d) Employee Benefits Expense	26,509	27,092	29,906	1,15,048
(e) Finance Costs	5,959	5,757	6,260	24,404
(f) Depreciation and amortisation expense	8,915	10,470	8,494	36,342
(g) Other expenses	41,197	40,245	39,674	1,59,918
<b>Total Expenses</b>	<b>1,29,009</b>	<b>1,25,095</b>	<b>1,31,794</b>	<b>5,28,645</b>
<b>3 Profit before Exceptional item and tax from continuing operations (1) - (2)</b>	<b>25,012</b>	<b>18,844</b>	<b>17,317</b>	<b>85,887</b>
4 Exceptional Item (Refer Note 6)	-	-	(674)	(674)
<b>5 Profit before tax from continuing operations (3) + (4)</b>	<b>25,012</b>	<b>18,844</b>	<b>16,643</b>	<b>85,213</b>
<b>6 Tax Expense/(benefit)</b>				
Current Tax	6,880	(6,731)	2,192	4,031
Deferred Tax (Refer Note 3)	(15,182)	10,700	3,767	23,948
<b>7 Profit for the period / year from continuing operations (after tax) (5) - (6)</b>	<b>33,314</b>	<b>14,875</b>	<b>10,684</b>	<b>57,234</b>

For APOLLO HOSPITALS ENTERPRISE LTD.

  
**Suneeta Reddy**  
Managing Director

**Apollo Hospitals Enterprise Limited**  
**Corporate Identity Number : L85110TN1979PLC008035**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu**  
**Tel No. 44-28290956 , Email : investor.relations@apollohospitals.com**  
**Website: www.apollohospitals.com**

**Statement of Unaudited Standalone Financial Results for the three months ended June 30, 2022**

(Rs. in lakhs)

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b><u>Discontinued Operations (Refer Note 4)</u></b>				
a) Profit before tax for the period / year from discontinued operations	-	757	6,639	14,248
b) Tax expense of discontinued operations	-	265	2,320	4,979
<b>8 Profit after tax for the period / year from discontinued operations(a) - (b)</b>	<b>-</b>	<b>492</b>	<b>4,319</b>	<b>9,269</b>
<b>9 Profit after tax for the period / year (7) + (8)</b>	<b>33,314</b>	<b>15,367</b>	<b>15,003</b>	<b>66,503</b>
<b>10 Other Comprehensive Income/ (Loss)</b>				
Items that will not be reclassified to Profit and Loss				
Remeasurement gains/(losses) on defined benefit plan	457	605	61	(345)
-Tax on above	(115)	(211)	(21)	121
<b>Total Other Comprehensive Income/ (Loss)</b>	<b>342</b>	<b>394</b>	<b>40</b>	<b>(224)</b>
<b>11 Total Comprehensive Income for the period/year (9) + (10)</b>	<b>33,656</b>	<b>15,761</b>	<b>15,043</b>	<b>66,279</b>
12 Paid-up equity share capital (Face value Rs.5/- per share)				7,189
13 Reserves ( excluding Revaluation Reserves)				6,03,881
<b>14 Earnings per equity share of Rs.5/- each</b>				
Basic and Diluted EPS for the period/year (Rs.)	*23.17	*10.69	*10.44	46.25
<b>15 Earnings per equity share of Rs.5/- each (from continuing operations)</b>				
Basic and Diluted EPS for the period/year (Rs.)	*23.17	*10.35	*7.44	39.80
<b>16 Earnings per equity share of Rs.5/- each (from discontinued operations)</b>				
Basic and Diluted EPS for the period/year (Rs.)	-	*0.34	*3.00	6.45
<b>Additional Information :-</b>				
<b>Earnings before finance costs, tax, depreciation and amortization, exceptional items (EBITDA) - Continuing operations (Refer Foot Note 1)</b>	<b>38,834</b>	<b>33,205</b>	<b>31,231</b>	<b>1,41,934</b>

\*Not annualised

**Foot Notes:**

1 The Company has presented Earnings before Finance costs, Tax, Depreciation, Amortization, Other income and Exceptional items (EBITDA) additionally as part of Financial Results.

**For APOLLO HOSPITALS ENTERPRISE LTD**

*Suneeta Reddy*  
**Suneeta Reddy**  
**Managing Director**



## NOTES TO STANDALONE FINANCIAL RESULTS:

1. The standalone financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three months ended June 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 10, 2022 and August 11, 2022 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three months ended June 30, 2022.
2. The standalone financial results for the three months ended March 31, 2022 are the balancing figures between the audited standalone figures of the full financial year and the unaudited year to date standalone figures for the nine months ending December 31, 2021, which were subject to limited review.
3. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ("the Amendment Act"). Accordingly, the Company has recognised provision for income tax for the quarter ended June 30, 2022 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Liability (net) as at April 1, 2022 and accounted tax credit of Rs.14,659 lakhs relating to the same in the current quarter.
4. The Company reorganised its pharmacy distribution business including the online technology platform Apollo 24|7 and the Company's shareholding in Apollo Medicals Private Limited (AMPL) (an associate) to Apollo Healthco Limited, a wholly owned subsidiary of the Company, for a consideration of Rs. 1,21,000 lakhs which was effected on March 16, 2022. The excess of the above-mentioned consideration over the net assets of Rs. 28,322 lakhs (net of taxes) has been transferred to capital reserve, the transaction being a common control transaction as per IND AS 103 "Business Combinations".

Consequently, the Pharmacy Distribution Business has been classified as Discontinued Operations and the prior period amounts have been accordingly re-presented. The impact of discontinued operations on income, expenses and tax is as under:

(Rs. In lakhs)

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
1 Income				
(a) Revenue from Operations	-	114,490	151,120	513,139
(b) Other Income	-	11	33	63
Total Income (a + b)	-	114,501	151,233	513,202
2 Expenses				
(a) Cost of Materials Consumed	-	-	-	-
(b) Purchases of Stock-in-Trade	-	106,668	141,020	473,167

For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director

Particulars		Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	(c) Changes in inventories of stock-in-trade	-	(3,407)	(4,241)	(9,651)
	(d) Employee Benefits Expense	-	2,582	1,896	9,072
	(e) Finance Costs	-	116	117	494
	(f) Depreciation and amortisation expense	-	848	1,106	3,690
	(g) Other expenses	-	6,937	4,696	22,182
	Total Expenses	-	113,744	144,594	498,954
3	Profit before Exceptional item and tax (1) - (2)	-	757	6,639	14,248
4	Exceptional Item (Refer Note 7)	-	-	-	-
5	Profit before tax (3) + (4)	-	757	6,639	14,248
6	Tax Expense/(benefit)	-	265	2,320	4,979
7	Profit for the period / year (after tax) (5) - (6)	-	492	4,319	9,269

Consequent to the above reorganisation, the Company is engaged only in Healthcare business and therefore has only one reportable segment as at March 31, 2022, in accordance with IND AS 108 "Operating Segments" ("IND AS 108"). On account of the said change in the composition of reportable segments, the corresponding information relating to earlier periods / year have been restated as prescribed by IND AS 108.

- Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999 lakhs.

The utilisation of the QIP Issue proceeds upto June 30, 2022 is as follows:

Particulars	Amount in Rs. Lakhs
Fees paid to Lead Managers	1,071
Foreclosure of debts	24,846
Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited	41,000
Balance amounts placed in Mutual Funds pending deployment as on June 30, 2022	50,082

For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director

6. The Company had received approval from the Regional Director, Ministry of Corporate Affairs on June 28, 2021 for the Scheme of Amalgamation with the following wholly owned subsidiary companies, with the Appointed Date being April 1, 2020:
- a. Apollo Home Healthcare (India) Limited and
  - b. Western Hospitals Corporation Private Limited

Consequent to giving effect to the said Scheme of Amalgamation, the Company has created a provision against loan of Rs. 674 lakhs extended by Western Hospitals Corporation Private Limited, in earlier years, to Apollo Lavasa Health Corporation Limited, a subsidiary, due to its adverse business conditions. This provision has been disclosed under Exceptional Items in the standalone financial results for the quarter ended June 30, 2021 and year ended March 31, 2022.

7. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai  
Date: August 11, 2022

Dr. Prathap C Reddy  
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Apollo Hospitals Enterprise Limited ("the Company"), for the three months ended June 30, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

VIKAS Digitally signed by  
VIKAS BAGARIA  
BAGARIA Date: 2022.08.11  
18:02:39 +05'30'

**Vikas Bagaria**  
Partner  
(Membership No. 060408)

Place: Bengaluru  
Date: 11 August 2022

## Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

### Statement of Unaudited Consolidated Financial Results for the three months ended June 30, 2022

(Rs. in lakhs )

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b>1 Income</b>				
(a) Revenue from Operations	3,79,560	3,54,643	3,76,021	14,66,264
(b) Other Income	1,606	3,072	2,464	7,814
<b>Total Income (a + b)</b>	<b>3,81,166</b>	<b>3,57,715</b>	<b>3,78,485</b>	<b>14,74,078</b>
<b>2 Expenses</b>				
(a) Cost of Materials Consumed	61,237	56,915	58,170	2,68,548
(b) Purchases of Stock-in-Trade	1,35,492	1,25,587	1,60,659	4,96,133
(c) Changes in inventories of stock-in-trade	(1,517)	(937)	(12,634)	(7,334)
(d) Employee Benefits Expense	44,742	44,662	44,349	1,78,652
(e) Finance Costs	9,272	9,490	9,468	37,864
(f) Depreciation and amortisation expense	14,778	16,640	14,056	60,070
(g) Other Expenses	90,532	82,092	73,490	3,11,753
<b>Total Expenses</b>	<b>3,54,536</b>	<b>3,34,449</b>	<b>3,47,558</b>	<b>13,45,686</b>
<b>3 Profit before share of profit/(loss) in associates / joint ventures and exceptional items (1) - (2)</b>	<b>26,630</b>	<b>23,266</b>	<b>30,927</b>	<b>1,28,392</b>
4 Share of profit/(loss) of an associates / a joint ventures	(1,202)	302	(415)	735
<b>5 Profit before exceptional item and tax (3) + (4)</b>	<b>25,428</b>	<b>23,568</b>	<b>30,512</b>	<b>1,29,127</b>
6 Exceptional Item (Refer Note 6)			29,411	29,411
<b>7 Profit before tax (5) + (6)</b>	<b>25,428</b>	<b>23,568</b>	<b>59,923</b>	<b>1,58,538</b>
<b>8 Tax Expenses</b>				
Current Tax (Refer Note 4)	8,532	3,392	5,726	23,773
Deferred Tax (Refer Note 3)	(15,482)	10,475	4,129	23,929
<b>9 Profit for the period/year (7) - (8)</b>	<b>32,378</b>	<b>9,701</b>	<b>50,068</b>	<b>1,10,836</b>
<b>10 Other Comprehensive Income / (Loss)</b>				
Items that will not be reclassified to Profit or Loss				
Remeasurement gains / (losses) on defined benefit plan	484	(297)	349	(1,494)
- Tax on above	(122)	104	(122)	522
<b>Total Other Comprehensive Income/ (Loss)</b>	<b>362</b>	<b>(193)</b>	<b>227</b>	<b>(972)</b>

For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director



## Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai - 28, Tamil Nadu

Tel No. 44-28290956 , Email : investor.relations@apollohospitals.com

Website: www.apollohospitals.com

### Statement of Unaudited Consolidated Financial Results for the three months ended June 30, 2022

(Rs. in lakhs )

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b>11 Total Comprehensive Income for the period (9) + (10)</b>	<b>32,740</b>	<b>9,508</b>	<b>50,295</b>	<b>1,09,864</b>
<b>Profit / (Loss) for the period attributable to:</b>				
Owners of the parent	31,711	9,014	48,928	1,05,562
Non-controlling interest	667	687	1,140	5,274
<b>Other Comprehensive Income/ (Loss) for the period attributable to:</b>				
Owners of the parent	365	(139)	230	(871)
Non-controlling interest	(3)	(54)	(3)	(101)
<b>Total Comprehensive Income / (Loss) for the period attributable to:</b>				
Owners of the parent	32,076	8,875	49,158	1,04,691
Non-controlling interest	664	633	1,137	5,173
<b>12 Paid-up equity share capital (Face value Rs.5/- per share)</b>				7,189
Reserves (excluding Revaluation Reserves)				5,54,345
<b>13 Earnings per equity share of Rs.5/- each</b>				
Basic and Diluted EPS for the period/year (Rs.)	*22.05	*6.27	*34.03	73

\*Not annualised

For APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
Suneeta Reddy  
Managing Director

**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu**  
**Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities**

( Rs. in lakhs )

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b>1. Segment Revenue</b>				
a) Healthcare Services	2,03,207	1,87,926	1,94,124	8,01,319
b) 24/7 Digital (Refer Note 4)	626	47	-	47
c) Clinics	29,301	29,670	30,900	1,30,024
d) Others	116	104	106	423
e) Pharmacy Distribution	1,47,292	1,37,402	1,51,200	5,36,050
<b>SUB - TOTAL</b>	<b>3,80,542</b>	<b>3,55,149</b>	<b>3,76,330</b>	<b>14,67,863</b>
Less : Intersegmental Revenue	982	506	309	1,599
<b>Income from Operations</b>	<b>3,79,560</b>	<b>3,54,643</b>	<b>3,76,021</b>	<b>14,66,264</b>
<b>2. Segment Results</b>				
a) Healthcare Services	36,999	27,166	28,677	1,33,047
b) 24/7 Digital (Refer Note 4)	(14,071)	(1,610)		(1,610)
c) Clinics	597	1,301	2,573	10,233
d) Others	56	376	(41)	501
e) Pharmacy Distribution	10,715	2,451	6,722	16,271
<b>SUB - TOTAL</b>	<b>34,296</b>	<b>29,684</b>	<b>37,931</b>	<b>1,58,442</b>
Less: (i) Finance Cost	9,272	9,490	9,468	37,864
Add: (ii) Other un-allocable income, (net of expenditure)	1,606	3,072	2,464	7,814
Add: (iii) Exceptional item (Refer Note 6)	-	-	29,411	29,411
Add: (iv) Share of profit of associates / joint ventures	(1,202)	302	(415)	735
<b>Profit / (Loss) Before Tax</b>	<b>25,428</b>	<b>23,568</b>	<b>59,923</b>	<b>1,58,538</b>

FOR APOLLO HOSPITALS ENTERPRISE LTD.

*Suneeta Reddy*  
**Suneeta Reddy**  
**Managing Director**

**Apollo Hospitals Enterprise Limited**  
**Regd. Office : No. 19 Bishop Gardens, Raja Annamalaipuram, Chennai-28, Tamil Nadu**  
**Consolidated Segment wise Revenue, Results, Segment Assets and Segment Liabilities**

( Rs. in lakhs )

Particulars	Three months ended 30/06/2022	Preceding Three months ended 31/03/2022	Corresponding Three months ended 30/06/2021	Previous year ended 31/03/2022
	Unaudited	Refer Note 2	Unaudited	Audited
<b>3. Capital employed</b>				
<b>a) Healthcare Services *</b>				
Segment Assets	9,43,282	9,48,536	9,64,486	9,48,536
Segment Liabilities	(3,11,179)	(2,96,894)	(3,25,441)	(2,96,894)
<b>b) 24/7 Digital</b>				
Segment Assets	16,638	13,326	-	13,326
Segment Liabilities	(10,779)	(6,339)	-	(6,339)
<b>c) Clinics</b>				
Segment Assets	1,14,753	1,12,958	1,14,472	1,12,958
Segment Liabilities	(84,062)	(83,682)	(85,593)	(83,682)
<b>d) Others</b>				
Segment Assets	3,844	3,888	3,960	3,888
Segment Liabilities	(1,754)	(1,760)	(1,727)	(1,760)
<b>e) Pharmacy Distribution</b>				
Segment Assets	1,33,943	1,22,620	1,32,109	1,22,620
Segment Liabilities	(55,508)	(49,158)	(46,858)	(49,158)
<b>f) Unallocated</b>				
Segment Assets	1,45,260	1,17,888	1,06,500	1,17,888
Segment Liabilities	(3,00,254)	(3,19,072)	(3,51,904)	(3,19,072)
<b>Total</b>	<b>5,94,184</b>	<b>5,62,311</b>	<b>5,10,004</b>	<b>5,62,311</b>
* Includes Capital employed in various hospital projects under construction	4,909	4,545	27,010	4,545

For APOLLO HOSPITALS ENTERPRISE LTD.

  
**Suneeta Reddy**  
**Managing Director**



## NOTES TO CONSOLIDATED FINANCIAL RESULTS:

1. The consolidated financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three months ended June 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 10, 2022 and August 11, 2022 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the consolidated financial results for the three months ended June 30, 2022.
2. The consolidated financial results for the three months ended March 31, 2022 are the balancing figures between the audited consolidated figures of the full financial year and the unaudited year to date consolidated figures for the nine months ended December 31, 2021, which were subject to limited review.
3. The Company has exercised the option of lower tax permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 ('the Amendment Act"). Accordingly, the Company has recognised provision for income tax for the quarter ended June 30, 2022 basis the rate provided in the said Amendment Act. The Company has re-measured the opening balance of Deferred Tax Liability (net) as at April 1, 2022 and accounted tax credit of Rs.14,659 lakhs relating to the same in the current quarter.
4. The Company reorganised its pharmacy distribution business including the online technology platform Apollo 24|7 and the Company's shareholding in Apollo Medicals Private Limited (AMPL) (an associate) to Apollo Healthco Limited, a wholly owned subsidiary of the Company, for a consideration of Rs. 1,21,000 lakhs which was effected on March 16, 2022. This being a common control transaction under IND AS 103 "Business Combinations" there is no impact of this reorganisation in the consolidated financial results. Current tax for the quarter and year ended March 31, 2022 includes the provision for capital gains tax of Rs. 8,819 lakhs relating to the above reorganisation.

With regard to the segment reporting, the Company has identified the following operating and reportable segments consequent to the above-mentioned reorganisation:

- (a) Healthcare (represents hospitals and hospitals based services)
- (b) Pharmacy Distribution (represents the business of procurement and distribution of pharmaceutical, fast moving consumer goods (FMCG) and private label products)
- (c) Clinics (includes clinics and diagnostics)
- (d) 24|7 Digital (represents business from various services using the digital platform)
- (e) Others (includes revenue, assets and liabilities of components not engaged in any of the above segments)

For the period prior to March 16, 2022, the revenue, expenses, assets and liabilities relating to 24|7 Digital segment form part of Pharmacy Distribution segment, the corresponding segment information for earlier periods have not been restated to reflect the change in the segment information considering 24|7 Digital operations were integral to the Pharmacy Distribution segment and were not distinctively tracked.

For APOLLO HOSPITALS ENTERPRISE LTD.

  
Sunesta Reddy  
Managing Director

5. Pursuant to the approval accorded by the members through Postal Ballot to raise equity proceeds upto a sum of Rs 150,000 lakhs, the Company completed a Qualified Institutional Equity (QIP) placement in January 2021, allotting an additional 46,59,498 equity shares at a price of Rs 2,511 per share (face value Rs 5/- each) aggregating to a sum of Rs 116,999 lakhs.

The utilisation of the QIP Issue proceeds upto June 30, 2022 was as follows:

<b>Particulars</b>	<b>Amount in Rs. Lakhs</b>
Fees paid to Lead Managers	1,071
Foreclosure of debts	24,846
Acquisition of equity stake in Apollo Multi Speciality Hospitals Limited	41,000
Balance amounts placed in Mutual Funds pending deployment as on June 30 2022	50,082

6. The Company completed the acquisition of an additional 50% stake held by Gleneagles Development Pte Limited (erstwhile joint venturer) in Apollo Multi Specialty Hospitals Limited (AMSHL) (formerly known as Apollo Gleneagles Hospitals Limited), Kolkata on 22 April 2021 for a consideration of Rs. 41,000 lakhs. Consequently, AMSHL became a wholly owned subsidiary of the Company and has been consolidated effective from 22nd April 2021. The resultant goodwill of Rs. 53,714 lakhs has been presented within the Healthcare segment.

The acquisition date fair value of the existing equity interest in AMSHL compared to its carrying amount resulted in a gain of Rs.29411 lakhs, which has been included under exceptional items.

7. Assam Hospitals Limited (AHL), a subsidiary company, completed the acquisition of 64.42% of equity stake in Asclepius Hospitals and Healthcare Private Limited (AHHPL), Guwahati on November 12, 2021, for a consideration of Rs.10,000 lakhs. Consequently, AHHPL became a subsidiary of AHL with effect from the said date.

The Company has completed the provisional purchase price allocation in respect of the identifiable assets acquired and liabilities assumed, resulting in a goodwill of Rs. 1,153 lakhs. The goodwill arising out of the acquisition is presented within the Healthcare segment.

8. The Honourable High Court of Karnataka on October 8, 2021 has set aside the order of the State of Karnataka, Revenue Department ("Revenue Department") initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company alleging non-compliance of certain conditions associated with the allotment of land to the said subsidiary company and have remitted it back to the Revenue Department for reconsideration and disposal. The Revenue Department had issued a show cause notice dated 9 February 2022 seeking explanations as to why the original order needs to be withdrawn for which the subsidiary company had filed a detailed response explaining how there are no violations of the conditions relating to the allotment of the land. Based on legal opinion received, the subsidiary company has adequate grounds to demonstrate compliance with applicable conditions and therefore is of the opinion that the matter would be settled in their favour.

For APOLLO HOSPITALS ENTERPRISE LTD.

  
Suneeta Reddy  
Managing Director

9. The aforesaid financial results are also available on the Company's website ([www.apollohospitals.com](http://www.apollohospitals.com)).

For APOLLO HOSPITALS ENTERPRISE LIMITED

Place: Chennai  
Date: August 11, 2022

Dr. Prathap C Reddy  
Executive Chairman

For APOLLO HOSPITALS ENTERPRISE LTD.  
  
Suneeta Reddy  
Managing Director



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF Apollo Hospitals Enterprise Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Apollo Hospitals Enterprise Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint ventures for the three months ended June 30, 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Name of the Company	Relationship
Apollo Hospitals Enterprise Limited (AHEL)	Parent
Apollo Home Healthcare Limited (AHHL)	Subsidiary
AB Medical Centers Limited	Subsidiary
Samudra Health Care Enterprises Limited	Subsidiary
Imperial Hospitals & Research Centre Limited	Subsidiary
Apollo Hospitals (UK) Limited	Subsidiary
Apollo Health and Lifestyle Limited (AHLL)	Subsidiary
Apollo Nellore Hospital Limited	Subsidiary
Sapein Bio-sciences Private Limited	Subsidiary

# Deloitte Haskins & Sells LLP

<b>Name of the Company</b>	<b>Relationship</b>
Apollo Hospitals International Limited (AHIL)	Subsidiary
Apollo Lavasa Health Corporation Limited	Subsidiary
Apollo Rajshree Hospital Private Limited	Subsidiary
Future Parking Private Limited	Subsidiary
Total Health	Subsidiary
Apollo Hospitals Singapore Pte Limited	Subsidiary
Assam Hospitals Limited (Assam)	Subsidiary
Medics International Lifesciences Limited	Subsidiary
Apollo Multi Specialty Hospitals Limited (AMSHL)	Subsidiary
Apollo HealthCo Limited (AHL)	Subsidiary
Apollo Hospitals North Limited	Subsidiary
Alliance Dental Care Limited	Subsidiary of AHLL
Apollo Dialysis Private Limited	Subsidiary of AHLL
Apollo Sugar Clinics Limited	Subsidiary of AHLL
Apollo Speciality Hospitals Private Limited	Subsidiary of AHLL
AHLL Diagnostics Limited	Subsidiary of AHLL
AHLL Risk Management Private Limited	Subsidiary of AHLL
Surya Fertility Center Private Limited	Stepdown Subsidiary of AHLL
Apollo Bangalore Cradle Limited	Stepdown Subsidiary of AHLL
Kshema Healthcare Private Limited	Stepdown Subsidiary of AHLL
Asclepius Hospitals and Healthcare Private Limited	Subsidiary of Assam
Apollo CVHF Limited	Subsidiary of AHIL
Apollo Pharmacy Limited	Subsidiary of AMPL
Apollo Pharmalogistics Private Limited	Subsidiary of AMPL
Family Health Plan Insurance (TPA) Limited	Associate
Indraprastha Medical Corporation Limited	Associate
Stemcyte India Therapeutics Private Limited	Associate
Apollo-Amrish Oncology Services Private Limited	Associate of AHIL
Apollo Medical Private Limited (AMPL)	Associate of AHL
Apollo Gleneagles PET-CT Private Limited	Joint venture
ApoKos Rehab Private limited	Joint venture

- Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- We draw attention to Note 8 to the Statement in respect of proceedings initiated against the subsidiary, Imperial Hospitals & Research Centre Limited, by the Government of Karnataka. Our conclusion on the Statement is not modified in respect of this matter.



# Deloitte Haskins & Sells LLP

7. We did not review the interim financial results of 23 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total revenues of Rs. 37,773 Lakhs for the three months ended June 30, 2022, total net profit after tax of Rs. 2,946 Lakhs for the three months ended June 30, 2022 and total comprehensive income of Rs. 2,939 Lakhs for the three months ended June 30, 2022, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 1,179 Lakhs for the three months ended June 30, 2022 and total comprehensive loss of Rs. 1,184 Lakhs for the three months ended June 30, 2022, as considered in the Statement, in respect of 4 associates (including 2 subsidiaries of 1 associate) and 1 joint venture, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

8. The consolidated unaudited financial results includes the interim financial results of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenue of Rs. NIL for the three months ended June 30, 2022, total profit after tax of Rs. 89 Lakhs for the three months ended June 30, 2022 and total comprehensive income of Rs. 89 Lakhs for the three months ended June 30, 2022, as considered in the Statement. The consolidated unaudited financial results also includes the Group's share of loss after tax of Rs. 23 Lakhs for the three months ended June 30, 2022 and total comprehensive loss of Rs. 23 Lakhs for the three months ended June 30, 2022, as considered in the Statement, in respect of 1 associate and 1 joint venture, based on their interim financial results which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial results certified by the Management.

For **Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

VIKAS Digitally signed by  
VIKAS BAGARIA  
Date: 2022.08.11  
18:01:10 +05'30'  
BAGARIA

**Vikas Bagaria**  
Partner  
(Membership No. 060408)

Place: Bengaluru  
Date: 11 August 2022